- Home
- CEV vs DRRX Comparison
CEV vs DRRX Comparison
Compare CEV & DRRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEV
- DRRX
- Stock Information
- Founded
- CEV 1999
- DRRX 1998
- Country
- CEV United States
- DRRX United States
- Employees
- CEV N/A
- DRRX N/A
- Industry
- CEV Finance/Investors Services
- DRRX Biotechnology: Pharmaceutical Preparations
- Sector
- CEV Finance
- DRRX Health Care
- Exchange
- CEV Nasdaq
- DRRX Nasdaq
- Market Cap
- CEV 67.8M
- DRRX 59.3M
- IPO Year
- CEV N/A
- DRRX 2000
- Fundamental
- Price
- CEV $9.47
- DRRX $1.92
- Analyst Decision
- CEV
- DRRX Hold
- Analyst Count
- CEV 0
- DRRX 1
- Target Price
- CEV N/A
- DRRX N/A
- AVG Volume (30 Days)
- CEV 19.6K
- DRRX 3.1M
- Earning Date
- CEV 01-01-0001
- DRRX 08-12-2025
- Dividend Yield
- CEV 4.23%
- DRRX N/A
- EPS Growth
- CEV N/A
- DRRX N/A
- EPS
- CEV 0.36
- DRRX N/A
- Revenue
- CEV N/A
- DRRX $1,657,000.00
- Revenue This Year
- CEV N/A
- DRRX N/A
- Revenue Next Year
- CEV N/A
- DRRX $673.00
- P/E Ratio
- CEV $29.36
- DRRX N/A
- Revenue Growth
- CEV N/A
- DRRX N/A
- 52 Week Low
- CEV $8.83
- DRRX $0.48
- 52 Week High
- CEV $10.91
- DRRX $2.64
- Technical
- Relative Strength Index (RSI)
- CEV 45.58
- DRRX 82.21
- Support Level
- CEV $9.37
- DRRX $1.86
- Resistance Level
- CEV $9.59
- DRRX $1.92
- Average True Range (ATR)
- CEV 0.07
- DRRX 0.04
- MACD
- CEV -0.01
- DRRX -0.03
- Stochastic Oscillator
- CEV 34.24
- DRRX 90.00
About CEV Eaton Vance California Municipal Income Trust Shares of Beneficial Interest
Eaton Vance CA Muni Income Trust is a non-diversified closed-end investment company. The company's investment objective is to provide current income exempt from regular federal income tax and California state personal income taxes. It invests in municipal obligations, issued by the State of California or its political subdivisions, agencies, authorities and instrumentalities and also has some exposure to corporate bonds.
About DRRX DURECT Corporation
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories, which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from Europe.